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Resveratrol Induces Vascular Smooth Muscle Cell
Differentiation through Stimulation of SirT1 and AMPK
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Abstract
Phenotypic plasticity in vascular smooth muscle cells (VSMC) is necessary for vessel maintenance, repair and adaptation to
vascular changes associated with aging. De-differentiated VSMC contribute to pathologies including atherosclerosis and
intimal hyperplasia. As resveratrol has been reported to have cardio- protective effects, we investigated its role in VSMC
phenotypic modulation. We demonstrated the novel finding that resveratrol promoted VSMC differentiation as measured
by contractile protein expression, contractile morphology and contraction in collagen gels. Resveratrol induced VSMC
differentiation through stimulation of SirT1 and AMPK. We made the novel finding that low or high dose resveratrol had an
initially different mechanism on induction of differentiation. We found that low dose resveratrol stimulated differentiation
through SirT1-mediated activation of AKT, whereas high dose resveratrol stimulated differentiation through AMPKmediated inhibition of the mTORC1 pathway, allowing activation of AKT. The health effects of resveratrol in cardiovascular
diseases, cancer and longevity are an area of active research. We have demonstrated a supplemental avenue where-by
resveratrol may promote health by maintaining and enhancing plasticity of the vasculature.
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AKT pathway controls cellular metabolism, growth and apoptosis
[5]. We have previously demonstrated that AKT2 activation was
essential for VSMC differentiation [3]. Furthermore, we have
demonstrated that the AMPK signaling pathway, which controls
cellular energy homeostasis, inhibits mTORC1 and thereby
promotes differentiation through activation of AKT [4]. These
differentiation and de-differentiation promoting molecules are
intimately intertwined and their activation or inhibition is
dynamically influenced by vessel homeostasis.
Resveratrol is a polyphenol found in the skin of grapes, berries
and peanuts that can activate AMPK and sirtuins [6,7].
Resveratrol possess antioxidant properties [6], increases nitric
oxide synthase production [8] and improves mitochondrial
function [6–9] by activating AMPK and sirtuins.
Sirtuins are a family of proteins that function as NAD+
dependent deacetylases and as such are tied to the metabolic
state of the cell. There are seven mammalian sirtuins (SirT1-7),
each functioning in a distinct capacity, but ultimately tied to
cellular metabolism. SirT1 is the mammalian homologue of Sir2,
which was first identified in Saccharomyces cerevisiae [10], and is
recognized for its association with longevity [11–13].
In the current study, we investigated the effect of resveratrol on
promotion of VSMC differentiation in human VSMC
(HuVSMC). We tested the hypothesis that resveratrol treatment
increases levels of SirT1, which promotes VSMC differentiation.
We made the novel finding that low or high dose resveratrol had a
differential mechanism on induction of differentiation. We found
that low dose resveratrol stimulated differentiation through SirT1-

Introduction
Vascular smooth muscle cells (VSMCs) are not terminally
differentiated; they are capable of responding to both intrinsic and
extrinsic vessel signaling and can modify their phenotype in
physiological and pathophysiological settings. This capacity for
reversible phenotypic switching is a property of a mature VSMC,
where the primary function is to regulate blood vessel diameter by
contracting or relaxing. Differentiated VSMCs proliferate slowly,
have low synthetic activity and express a specific set of contractile
proteins [1,2]. Growth factor stimulation in vitro, or in response to
injury in vivo, elicits a phenotype change; VSMC de-differentiate,
express reduced levels of contractile proteins, proliferate and can
migrate to the site of injury where they participate in vascular
repair and remodeling. The plasticity of VSMC creates an
adaptive, multifunctional smooth muscle layer within the artery.
The capacity for phenotypic modulation is a necessity for
maintenance and repair of the vessel in response to environmental
insults.
Several signaling pathways control phenotypic modulation.
These pathways are connected by reciprocal activation or
inhibition. Several key signaling molecules have been implicated
in differentiation, including mTORC1, AKT and AMPK [3,4].
The mTORC1 pathway controls cell size, primarily by altering
protein synthesis. Growth factor activation of this pathway
promotes VSMC de-differentiation and proliferation, while
mTORC1 inhibition promotes differentiation, by relieving the
classical S6K1-mediated negative feedback regulation of insulin
receptor substrate-1 (IRS-1) signaling to PI3K/AKT [3]. The
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mediated activation of AKT, whereas high dose resveratrol
stimulated differentiation through AMPK-mediated inhibition of
the mTORC1 pathway, allowing activation of AKT.

0.1%Tween 20 for 1 hour. Primary antibody (SM2-MHC or SMAlpha Actin, 1:100) were added to coverslips and incubated
overnight at 4uC. Primary antibodies were removed from coverslip
and washed three times in TBS/0.1%Tween 20. Secondary
antibodies (Alexa Fluor 568 Anti-Rabbit or Alexa Fluor 488 AntiMouse) were added to the coverslips for 1 hour. The secondary
antibodies were removed and the coverslips were washed three
times in TBS/0.1%Tween 20. DAPI stain was added for 5
minutes and the coverslips were washed with TBS/0.1%Tween
20. Coverslips were mounted on slides and analyzed on Zeiss LSM
510 Meta confocal microscope.

Materials and Methods
Materials
Antibodies against SirT1, phosphorylated ribosomal protein-S6
(Ser240/244), AMPK-a, phosphorylated AMPK-a (Thr172) and
phosphorylated AKT (Ser473) were purchased from Cell Signaling (Beverly, MA). Antibodies against b-tubulin and phosphorylated p70S6K (Thr421/Ser424) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). GAPDH antibody was purchased from Abcam (Cambridge, MA). Antibodies against smooth
muscle myosin heavy chain (SM2-MHC) and calponin along with
resveratrol and carbachol were purchased from Sigma-Aldrich (St.
Louis, MO). Pierce BCA protein assay kit was purchased from
Thermo Scientific (Rockford, IL). API-2 was purchased from
EMB Millipore (Darmstadt, Germany).

In Vitro Contraction Assay
HuVSMC were pre-treated with 3–5 mM resveratrol or control
for 24 hours prior to being trypsinized for experimentation.
Twenty-four well plates were coated with 3% BSA for 1 hour. A
suspension of Type I collagen (1 ng/mL), M199 media with 2.5%
fetal bovine serum and pre-treated VSMCs was prepared. 400 mL
of cell/collagen suspension was pipetted into the BSA-coated
plates and incubated at 37uC for 1 hour. 16105 VSMCs were
plated per collagen disc. Collagen discs were gently detached from
sides of well. Detached collagen discs were re-treated with the
same treatment that was administered prior to being suspended in
collagen and photographed over a time course. Area of collagen
discs was assessed using ImageJ.

Cell Culture
Human vascular smooth muscle cells (HuVSMC) were
purchased from Lifeline Cell Technology (Frederick, MD; FC0031) or isolated from vascular surgery patients or organ donor
tissue. The Dartmouth College Committee for the Protection of
Human Subjects reviewed the study project in detail. As the
specimens were to be destroyed and the cells are not immortalized
(destroyed after 10 passages), neither patient consent nor
Institutional Review Board approval was required. Tissues
obtained from patients or donors included renal artery, tibial
artery and femoral artery. Tissue was received in sterile saline.
Outer adventitial layer was dissected from medial layer and cells
were prepared from the medial layer using the explant method in
M199 media with 10% fetal bovine serum, penicillin, streptomycin, and L-glutamine. The cells were verified as smooth muscle
cells through staining of smooth muscle specific markers and the
lack of staining for FSP1, a fibroblast specific marker. VSMCs at
passages 2–7 were used for experiments. Data in each experiment
have been confirmed in VSMCs from at least two different
preparations. Cells were grown to 70–80% confluence and 24
hours prior to resveratrol or control treatment, cells were
transferred to media containing 2.5% fetal bovine serum for the
duration of the experiment. Control treatment was the vehicle
utilized in the formulation of the drug treatment.

Organ Culture Model
Human tibial arteries were received in sterile saline, placed in
sterile cell culture dishes and cross-sectioned into rings 2 mm in
thickness. Tissue was maintained in M199 media with 10% fetal
bovine serum with or without resveratrol treatment. Media was
changed every other day until collected for western blot analysis.

Western Blot Analysis
Cells were washed with Hanks buffer and scraped in 50–100 mL
of lysis buffer (with protease inhibitors), centrifuged, and the
supernatant was collected. Protein content was determined by
BCA protein assay. Total cell extracts containing 16–20 mg of
protein were prepared in SDS sample buffer and subjected to
SDS-PAGE and western blot analysis. Proteins were transferred to
nitrocellulose membranes prior to immunodetection.

Transient Transfection of siRNA and Plasmid
Transient transfection of small interfering RNA (siRNA) was
performed via Nucleofector (Lonza Walkersville Inc., MD) as
previously described [3]. For gene knockdown, 500,000–1,000,000
cells were transfected with 8 mg siRNA and cultured in 2.5% fetal
bovine serum for 24–48 hours. Cells were then treated with
resveratrol for 24 hours and harvested for western blot. SirT1
siRNA (sc-40986) was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). Control siGENOME non-targeting siRNA (D001206-13-05) was purchased from Thermoscientific (Pittsburg,
PA) for use with the SirT1 siRNA experiments. AMPKa1 siRNA
(SI02622235) and a matching nonsilencing control siRNA were
purchased from Qiagen (Germantown, MD).
Transfection of SirT1 plasmid (#13812, Addgene, Cambridge
MA) was performed via Nucleofector as previously described [3].
For gene overexpression, 500,000–1,000,000 cells were transfected
with 8 mg SirT1 plasmid and cultured in 2.5% fetal bovine serum
for 24–48 hours. Cells were treated with resveratrol for 24 hours
and harvested for western blot analysis.

Morphology
HuVSMC were plated on coverslips. The same numbers of cells
were added to each coverslip. Cells were treated with 0–100 mM
resveratrol, in duplicate, for 24 hours. Cells were washed with
PBS, fixed with acetone/methanol (1:1) for 10 minutes and then
washed with PBS. Next, cells were stained with coomassie blue for
10 minutes and washed with PBS. Cover slips were allowed to air
dry and then were mounted on slides. Images of the cells were
captured using SPOTTM 5.0 software. Quantification of the total
cell area (mm2) at 40X magnification was obtained by measureing
three areas per duplicate treatment and then averaging the areas.

Immuno-Flourescence
HuVSMC were plated on coverslips. The same numbers of cells
were added to each coverslip. Cells were treated with 3 mM
resveratrol or control, in triplicate, for 24 hours. Coverslips were
washed with PBS and fixed acetone/methanol (1:1) for 10
minutes. Next, coverslips were washed twice with TBS/
0.1%Tween 20. Coverslips were blocked with 3% BSA in TBS/
PLOS ONE | www.plosone.org

2

January 2014 | Volume 9 | Issue 1 | e85495

Resveratrol Induces VSMC Differentiation

calponin contractile protein expression (Figure 2B). Furthermore,
we demonstrated that upon SirT1 overexpression, SM2-MHC
and calponin were significantly increased from the de-differentiated baseline state (Figure 2C). As a note, endogenous SirT1 is
visualized at higher exposures. Together, these data indicate that
SirT1 expression is necessary and sufficient for contractile protein
expression in cultured HuVSMC.

Statistical Analysis
Results are expressed as mean6SEM. Statistical differences
between groups were determined with a one-way analysis of
variance (ANOVA) with Newman-Keuls post-hoc test using
GraphPad Prism software. A p value less than 0.05 was considered
significant.

Results
Mechanism of Low Dose Resveratrol Induced Contractile
Protein Expression

Resveratrol Induces Differentiation in Human Vascular
Smooth Muscle Cells

In an effort to determine how SirT1 participates in resveratrolinduced contractile protein expression, we first examined whether
resveratrol activated the AKT pathway as we have previously
demonstrated that AKT2 activation was essential for VSMC
differentiation [3]. We found, with low dose resveratrol treatment
(3 mM), the AKT pathway was activated as demonstrated by an
increase in AKT phosphorylated at Ser473 (Figure 3A). Of note,
at the 24-hour time point, we did not observe significant AKT
activation with high dose resveratrol. Additionally, we verified,
using an isoform specific immunoprecipitation, that AKT2 was the
isoform activated following resveratrol treatment (Figure S3).
Next, in an effort to confirm that AKT activation was necessary
for low dose resveratrol-induced differentiation, we utilized a
specific inhibitor of AKT activation, API-2 [16]. We treated
HuVSMC with and without low dose resveratrol in the presence
or absence of API-2. We found that in the absence of AKT
activation, 3 mM resveratrol treatment was unable to induce
differentiation, as demonstrated by a lack of change in contractile
protein expression (Figure 3B). In addition, we verified that
inhibition of AKT activation prevented differentiation with low or
high dose resveratrol, indicating that AKT activation is necessary
for induction of differentiation with low or high dose resveratrol
(Figure S4).
Finally, to further verify the mechanism by which low dose
resveratrol induces differentiation, we conducted a SirT1 knockdown experiment in HuVSMC. Having demonstrated that that
low dose resveratrol, at 24 hours post treatment, activates AKT
and that high dose resveratrol, at 24 hours post treatment, did not
significantly induce AKT activation; we treated HuVSMC with
low dose resveratrol (3 mM) for 24 hours, after SirT1 knockdown.
We found that resveratrol treatment, in the control siRNA group
induced differentiation through stimulation of SirT1 and activation of AKT, as measured by an increase in contractile protein,
SirT1 expression and AKT activation. However, with an 80%
knockdown of SirT1, low dose resveratrol treatment did not
induce differentiation, as measured by lack of change in contractile
protein expression and absence of AKT activation. (Figure 3C).
Together, these data demonstrate that low dose resveratrol
stimulates SirT1, which is required for activation of AKT and
the induction of differentiation. Intriguingly, resveratrol treatment
above 3 mM did not significantly activate AKT, suggesting that
resveratrol treatment above 3 mM may have additional activity
that is independent of SirT1 activation of AKT.

To determine the effect of resveratrol on differentiation, we
used HuVSMC isolated from multiple donors and various vascular
beds, which were maintained in culture conditions. HuVSMC
cultured in serum are de-differentiated; they express low levels of
contractile proteins, they produce increased extracellular matrix,
they have a fibroblast-like morphology and they are proliferative.
Measurement of contractile protein expression, evaluation of
morphology and the capacity to contract are standard methods
that have been used to characterize vascular smooth muscle cell
phenotype [3,4].
We first performed a dose escalation experiment and monitored
markers of differentiation. HuVSMC were treated with 3–100 mM
resveratrol or control for 24 hours. Resveratrol treatment, at all
doses, induced expression of protein markers of differentiation,
including smooth muscle myosin heavy chain (SM2-MHC), the
most stringent marker of VSMC differentiation [1], and calponin
(Figure 1A).
Differentiated HuVSMC can also be qualified by using
characteristic changes in morphology. Differentiated HuVSMC
are spindle shaped with a reduced cellular area, when compared to
the large, fibroblast-like morphology of de-differentiated VSMC.
Resveratrol treatment (3–100 mM), promoted a change in cellular
morphology to the contractile phenotype with a statistically
significant decrease in two-dimensional cellular area (Figure 1B).
We further verified the results of the two-dimension morphology
analysis using immuno-fluorescence staining for VSMC markers
SM-Alpha Actin and SM2-MHC, which demonstrate diffuse
staining of contractile proteins with control treatment and
organized staining of contractile proteins with resveratrol treatment (Figure S1).
Contractile capacity is a powerful functional measure of VSMC
phenotype. Differentiated VSMC demonstrate an increased
capacity for in vitro contraction [14]. Resveratrol, at the minimum
effective dose of 3–5 mM, significantly increased HuVSMC
contraction in collagen discs, compared to control (Figure 1C).
We confirmed that resveratrol-induced contraction took place in a
time frame suggestive of protein up regulation and that it was as
effective as carbachol, a positive control for VSMC contraction
[15] (Figure S2). These combined data demonstrate that
resveratrol promoted a differentiated contractile phenotype in
cultured HuVSMC.

SirT1 Induces Changes in Contractile Proteins Indicative
of Differentiation

Mechanism of High Dose Resveratrol Induced Contractile
Protein Expression

As resveratrol induces a wide range of effects in endothelial,
epithelial and fibroblastic cells [6], we determined whether
resveratrol altered SirT1 protein expression in HuVSMC. We
found that resveratrol (3–100 mM) significantly increased SirT1
protein expression in HuVSMC (Figure 2A). To determine if
SirT1 was necessary and sufficient for VSMC differentiation, we
performed knockdown and overexpression experiments. We
demonstrated that a 70% knockdown of endogenous SirT1 using
siRNA significantly reduced basal levels of SM2-MHC and
PLOS ONE | www.plosone.org

We have demonstrated VSMC differentiation at higher dose
resveratrol treatment that is independent of SirT1 activation of
AKT. Provided that resveratrol is known to induce AMPK
activation [9,17], we hypothesized that high dose resveratrol
induces differentiation through AMPK activation.
We treated HuVSMC with resveratrol (3–100 mM) for 24 hours
and demonstrated that resveratrol treatment induced AMPK
3
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Figure 1. Resveratrol Induces Differentiation in HuVSMC. A, HuVSMC treated with increasing doses of resveratrol for 24 hours prior to
western blot assessment with primary antibodies as indicated. Bar graphs represent densitometric quantification. N = 5 experiments. Probability
values are indicated above bars: *p,0.05, **p,0.01, ***p,0.001 versus control. B, Cell morphology after resveratrol treatment. HuVSMC treated with
0, 3, 10, 30 and 100 mM resveratrol. 40X magnification. Bar graphs represent mean area change plus standard error of mean. N = 6, Probability values
are indicated above bars: **p,0.01, ***p,0.001 versus control. C, HuVSMC pretreated with 3 mM resveratrol for 24 hours contracted the collagen
disc, compared to control. Bar graphs represent mean area change plus standard error of mean. N = 2 experiments, in triplicate. Probability values are
indicated above bars: *p,0.05 versus control.
doi:10.1371/journal.pone.0085495.g001

activity as measured by AMPK phosphorylated at Thr172
(Figure 4A). We have previously shown that AMPK activation
induces HuVSMC differentiation via inhibition of the mTORC1/
S6K1 pathway, which allows activation of AKT [4]. We found
that resveratrol induced AMPK activity correlated with an
inhibition of the mTORC1 pathway as measured by phosphorylation of the mTORC1 substrate p70S6K and its substrate RPS6
(Figure 4B). Consistent with our hypothesis, resveratrol treatment
at 3 mM did not significantly activate AMPK or inhibit mTORC1,
suggesting that resveratrol treatment at this low dose is acting
independent of AMPK.
PLOS ONE | www.plosone.org

Finally, to further verify the mechanism by which high dose
resveratrol induces differentiation, we conducted an AMPK a1
knockdown experiment in HuVSMC.
Having demonstrated that low dose resveratrol does not
significantly activate AMPK or inhibit the mTORC1 pathway
(Figure 4A,B); we treated HuVSMC with high dose resveratrol
(30 mM) for 24 hours, after AMPK a1 knockdown. We found that
resveratrol treatment, in the control siRNA group induced
differentiation through activation of AMPK and subsequent
inhibition of mTORC1, as measured by an increase in contractile
protein expression, AMPK activation and a decrease in phos4
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Figure 2. SirT1 Induces Changes in Contractile Proteins Indicative of Differentiation. A, HuVSMC treated with increasing concentrations of
resveratrol for 24 hours before western blot assessment with primary antibodies as indicated. Bar graphs represent densitometric quantification. N = 9
experiments. Probability values are indicated above bars: *p,0.05, **p,0.01, ***p,0.001 versus control. B, HuVSMC were transfected with control
small interfering (si) RNA or SirT1 siRNA for 48 hours and then assessed by western blot with primary antibodies as indicated. Bar graphs represent
densitometric quantification. N = 2 experiments, in duplicate. Probability values are indicated above bars: *p,0.05, **p,0.01 versus control. C,
HuVSMC were transfected with control or SirT1 plasmid for 48 hours and then assessed by western blot with primary antibodies as indicated. At
higher exposures, endogenous SirT1 is present in this experiment (data not shown). Bar graphs represent densitometric quantification. N = 3
experiments. Probability values are indicated above bars: **p,0.01 versus control.
doi:10.1371/journal.pone.0085495.g002

verified, using AMPK a1 siRNA with low and high dose
resveratrol that in the absence of AMPK a1, low dose resveratrol
does induce a marker of differentiation, whereas high dose does
not; verifying that high dose resveratrol works through AMPK
(Figure S5).

phorylation of the mTORC1 substrate p70S6K and its substrate
RPS6. However, with a 50% knock down of AMPK a1, high dose
resveratrol treatment did not induce differentiation, as measured
by a lack of change in contractile protein expression and absence
of mTORC1 pathway inhibition (Figure 4C). Additionally, we

PLOS ONE | www.plosone.org
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Figure 3. Resveratrol Induced Differentiation in VSMC via SirT1-AKT Signaling. A, HuVSMC treated with increasing concentrations of
resveratrol for 24 hours before western blot assessment with primary antibodies as indicated. Bar graphs represent densitometric quantification. N = 9
experiments. Probability values are indicated above bars: *p,0.05 versus control. B, HuVSMC were treated with 20 mM API-2 one hour prior to
resveratrol or control treatment. Twenty-four hours following resveratrol treatment, cells were collected and assessed by western blot with primary
antibodies as indicated. Bar graphs represent densitometric quantification. N = 4 experiments. Probability values are indicated above bars: *p,0.05,
**p,0.01 versus control. C, HuVSMC were transfected with control siRNA or SirT1 siRNA for 24 hours, prior to treatment with 3 mM resveratrol or
control. Twenty-four hours after treatment, cells were collected and assessed by western blot with primary antibodies as indicated. Bar graphs
represent densitometric quantification. N = 3 experiments, in duplicate. Probability values are indicated above bars: *p,0.05, **p,0.01, ***p,0.001
versus control or ,p,0.01, ,,p,0.001 versus control+resveratrol.
doi:10.1371/journal.pone.0085495.g003

serum with or without resveratrol for 10 days. Resveratrol
treatment elicited changes in contractile and signaling proteins
consistent with the results from our in vitro cell culture (Figure 5).
Low dose resveratrol treatment (3 mM) significantly increased
SirT1 and activated AKT. High dose resveratrol treatment
(30 mM) significantly increased SirT1, activated AMPK, inhibited
the mTORC1 pathway as measured by phosphorylation of the
mTORC1 substrate p70S6K and its substrate RPS6 and increased
SM2-MHC. The result of this intact vessel model confirms our
findings from isolated smooth muscle cells; resveratrol stimulates
SirT1 and AMPK to induce differentiation.

Together, our data demonstrates the initial mechanism by
which resveratrol induces differentiation in HuVSMC is dependent on the dose of resveratrol that is administered. Low dose
resveratrol (3 mM) induces differentiation through stimulation of
SirT1 and activation of AKT, whereas high dose resveratrol
(30 mM) induces differentiation through stimulation of AMPK and
inhibition of the mTORC1 pathway, allowing activation of AKT.

Resveratrol Induced Differentiation in Intact Tissue
We have demonstrated that both SirT1 and AMPK are
stimulated by resveratrol and participate in the induction of
differentiation in cultured HuVSMC. To verify that these
signaling proteins play a role in phenotypic modulation in intact
vascular tissue, we utilized an organ culture model. In this model,
smooth muscle cells in the medial layer de-differentiate when the
vessel is cultured in media with serum growth factors. Intact rings
of human artery were cultured in media with 10% fetal bovine
PLOS ONE | www.plosone.org

Discussion and Conclusions
Vascular smooth muscle cell differentiation is a vital process in
the maintenance and repair of the vasculature. Loss of vascular
smooth muscle cell plasticity is one component in the progression
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Figure 4. AMPK Inhibits the mTORC1 Pathway to Induce Differentiation. A, HuVSMC treated with increasing concentrations of resveratrol
for 24 hours prior to western blot assessment with primary antibodies as indicated. Bar graphs represent densitometric quantification. Samples have
been normalized to GAPDH and then fold change from normalized values have been graphed. N = 5 experiments. Probability values are indicated
above bars: *p,0.05 versus control. B, HuVSMC treated with increasing concentrations of resveratrol for 24 hours prior to western blot assessment of
primary antibodies as indicated. Bar graphs represent densitometric quantification. Samples have been normalized to GAPDH and then fold change
from normalized values have been graphed. N = 3 experiments. Probability values are indicated above bars: *p,0.05, ***p,0.001 versus control. C,
HuVSMC were transfected with control siRNA or AMPK a1 siRNA for 24 hours, prior to treatment with 30 mM resveratrol or control. Twenty-four hours
after treatment, cells were collected and assessed by western blot with primary antibodies as indicated. Bar graphs represent densitometric
quantification. N = 4 experiments. Probability values are indicated above bars: *p,0.05, **p,0.01, ***p,0.001 versus control or ,p,0.01,
,,p,0.001 versus control+resveratrol.
doi:10.1371/journal.pone.0085495.g004

ing insulin sensitivity, mediating DNA repair and altering
mitochondria during energy adaptation [8,11,13,18].
AMPK is the master regulator of energy metabolism; it matches
energy use to energy demand by altering glycogen utilization,
carbohydrate and lipid metabolism, fatty acid uptake and
oxidation, and protein synthesis [19].
SirT1 and AMPK have a long history of co-existence and
inter-dependence for activation. AMPK has been proposed to
indirectly regulate SirT1 activity by altering NAD+ availability
[9,17]. Conversely, SirT1 deacetylation of LKB1, which
promotes LKB1 translocation to the cytoplasm and phosphorylation of AMPK, is thought to directly regulate AMPK activity
[20]. Ultimately, considering the shared roles AMPK and SirT1
play in basic energy metabolism it is no surprise that these
molecules are fundamental in regulating vasculature remodeling

of age-related vasculature deterioration. We have made the novel
finding that resveratrol induced differentiation through a dose
dependent mechanism. Low dose resveratrol induced differentiation through stimulation of SirT1, which activated AKT to induce
differentiation. High dose resveratrol induced differentiation
through activation of AMPK, which inhibited the mTORC1
pathway and relieved AKT inhibition, therefore-promoting
differentiation. Despite the dose of resveratrol utilized, the final
downstream effector for resveratrol-induced differentiation is
AKT.
Sirtuins are a family of enzymes that improve metabolic
function, which is intimately tied to protection against age-related
deterioration. Sirtuins control transcription factors associated with
decreasing inflammation, increasing fatty acid oxidation, increas-
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Figure 5. Resveratrol-Induced Differentiation in Whole Tissue. Tibial artery rings cultured for 10 days with resveratrol prior to western blot
assessment with primary antibodies as indicated. Bar graphs represent densitometric quantification. N = 3 experiments. Probability values are
indicated above bars: *p,0.05, ***p,0.001, versus control.
doi:10.1371/journal.pone.0085495.g005

through phenotypic modulation. Unique to our data, we
demonstrate that both SirT1 and AMPK regulate vascular
smooth muscle cell differentiation. The differentiation-signaling
pathway elicited by resveratrol treatment capitalizes on the fact
that both low dose, through SirT1 and high dose, through
AMPK, elicit robust differentiation (Figure 6). The final
messenger in either the SirT1 pathway or the AMPK pathway
to differentiation is AKT; we have previously demonstrated that
AKT2 activation is necessary for contractile protein expression
[3]. SirT1 is known to promote membrane localization and
activation of AKT via SirT1-dependent deacetylation of two
lysine residues in the PH (pleckstrin homology) domain of AKT
[21]. This SirT1-dependent deacetylation is necessary for AKT
to bind to PIP3 and is necessary for AKT phosphorylation and,
therefore, activation to occur. We have demonstrated that low
dose resveratrol treatment increases phosphorylation of AKT
and that knockdown of SirT1 eliminates activation of AKT
(Figures 3 and 6). These combined data demonstrate that
following low dose resveratrol treatment differentiation is
induced through SirT1 direct activation of AKT; an activity
that is independent of AMPK activation.
Furthermore, Ghosh et al. have demonstrated that SirT1
negatively regulates mTORC1 in mouse embryonic fibroblasts
[22]: SirT1 associates with TSC2, and the interaction of SirT1
with TSC2 was demonstrated to be necessary for mTORC1
inhibition. Additionally, consistent with our present experiments,
Ghosh et al. found a dose dependent effect of resveratrol on
mTORC1 inhibition; Ghosh found that resveratrol treatment
up to 25 mM stimulated SirT1 and negatively regulated the
mTORC1 pathway, but high dose resveratrol treatment
(100 mM), independent of SirT1, maintained mTORC1 inhibition. Consistent with our findings in Figure 4, we suggest that
the resveratrol-induced SirT1-independent inhibition of the
mTORC1 pathway is mediated by stimulation of AMPK. High
dose resveratrol treatment therefore, induces contractile protein
PLOS ONE | www.plosone.org

Figure 6. Model of Resveratrol Signaling in HuVSMC Differentiation. Resveratrol stimulates multiple second messengers that lead to
AKT activation and the induction of differentiation. Low dose resveratrol
stimulates SirT1, which activates AKT to induce differentiation. High
dose resveratrol stimulates AMPK, which inhibits the mTORC1 pathway
relieving the S6K1 inhibition on IRS-1, allowing activation of AKT and
the induction of differentiation. Ultimately, resveratrol induces a multisignaling cascade that results in robust vascular smooth muscle
differentiation.
doi:10.1371/journal.pone.0085495.g006

expression through AMPK activation and inhibition of the
mTORC1 pathway, leading to activation of AKT and the
induction of differentiation.
In this study, we have demonstrated that the polyphenol,
resveratrol, that is heralded to prevent a broad range of diseases
[23], can amplify a web of second messengers that leads to
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robust induction of vascular smooth muscle cell differentiation.
This broader-multi-pathway stimulation allows for a rapid and
robust induction of differentiation.

(TIF)
Figure S3 Resveratrol Activates AKT2, but not AKT1 or
3. A, HuVSMC treated with 3 mM resveratrol or control for 24
hours prior to collection for immunoprecipitation (IP) with AKT2.
Lysate was blotted back (BB) for activated AKT with antibody
against phosphorylated AKT. B, HuVSMC treated with 3 mM
resveratrol or control for 24 hours prior to collection for
immunoprecipitation (IP) with AKT1 or AKT3. Lysate was
blotted back (BB) for activated AKT with antibody against
phosphorylated AKT.
(TIF)

Conclusions
Taken together, our experiments have demonstrated that
resveratrol may be a unique drug for eliciting vascular smooth
muscle cell differentiation; treatment with resveratrol activates
multiple second messengers leading to differentiation. Ultimately, resveratrol treatment induces both SirT1 and AMPK and
these molecules translate the vasculature crosstalk into activation
of AKT and phenotypic modulation of the smooth muscle cells.
Together, SirT1 and AMPK function as key coordinators of
signaling pathways that regulate long term vasculature plasticity.

Figure S4 AKT Activation is Necessary for Low or High
Dose Resveratrol-Induced Differentiation. HuVSMC were
treated with 20 mM API-2 one-hour prior to resveratrol or control
treatment. Twenty-four hours following resveratrol treatment, cells
were collected and assessed by western blot with primary
antibodies as indicated. N = 2 experiments.
(TIF)

Supporting Information
Figure S1 Resveratrol Stimulates a Contractile Morphology. HuVSMC were treated with 3 mM resveratrol or
control for 24 hours. Cells were stained for SM2-MHC or SMAlpha Actin (green) and the nucleus (blue). Images were captured
on confocal microscope.
(TIF)

Figure S5 AMPK is Necessary for High Dose Resveratrol-Induced Differentiation. HuVSMC were transfected
with control siRNA or AMPK a1 siRNA for 24 hours, prior to
treatment with resveratrol or control. Twenty-four hours after
treatment, cells were collected and assessed by western blot with
primary antibodies as indicated. N = 2 experiments.
(TIF)

Figure S2 Resveratrol Stimulates HuVSMC to Contract.
A, Representative images of contracted collagen discs treated with
3 mM resveratrol or control at 27 hours. Cells were pre-treated for
24 hours prior to being placed in collagen matrix. N = 2
experiments, in triplicate. B, HuVSMC were treated with
100 mM carbachol- a positive control of VSMC contraction,
3 mM resveratrol or control for 24 hours prior to measurement of
contracted collagen disc. Bar graphs represent mean area change
plus standard error of mean. N = 2 experiments, in triplicate.
Probability values are indicated above bars: *p,0.05, versus
control. C, HuVSMC treated with 5 mM resveratrol or control for
2 or 3 hours prior to measurement of contracted collagen disc,
demonstrating as early as two hours post treatment, resveratrol
stimulates contraction. Bar graphs represent mean area change
plus standard error of mean. N = 2 experiments, in triplicate.
Probability values are indicated above bars: *p,0.05, versus
control.
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